• 1
    Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice guidelines (8th edition). Chest. 2008;133:546S592S.
  • 2
    Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48:854906.
  • 3
    Amsterdam EA. Did you know? Updated guidelines for antithrombotic therapy in atrial fibrillation. Prev Cardiol. 2001;4:135136.
  • 4
    Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54:12801289.
  • 5
    Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:17291736.
  • 6
    Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927934.
  • 7
    Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156:23112316.
  • 8
    Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822827.
  • 9
    Mendelson G, Aronow WS. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke. J Am Geriatr Soc. 1998;46:14231424.
  • 10
    Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA. 2001;285:28642870.
  • 11
    Khumri TM, Idupulapati M, Rader VJ, et al. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol. 2007;99:17331736.
  • 12
    National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1S266.
  • 13
    Aronow WS. Acute and chronic management of atrial fibrillation in patients with late-stage CKD. Am J Kidney Dis. 2009;53:701710.
  • 14
    Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009;2:3337.